Market
Amycretin advances to phase 3 trials by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Novo Nordisk's official press releases or clinical trial registries
Story
Novo Nordisk's Amycretin Achieves 22% Weight Loss in Early Trial, Shares Jump 11%
Jan 24, 2025, 11:05 AM
Novo Nordisk announced positive results from an early-stage clinical trial of its next-generation experimental obesity drug, amycretin. In the phase 1b/2a trial involving 125 participants with overweight or obesity, those treated with amycretin achieved up to 22% weight loss after 36 weeks. Amycretin is a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous injection. Following the announcement, Novo Nordisk's shares surged by as much as 11%, the most in a month.
View original story
Similar markets
Positive results • 25%
Trial halted • 25%
Mixed results • 25%
Negative results • 25%
Successful with significant results • 25%
Successful with moderate results • 25%
Unsuccessful • 25%
Trial not initiated • 25%
